Legend Biotech Corporation (LEGN) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Somerset, NJ, アメリカ. 現CEOは Ying Huang.
LEGN を有する IPO日 2020-06-05, 2,600 名の正社員, に上場 NASDAQ Global Select, 時価総額 $3.46B.
Legend Biotech Corporation is a biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other diseases across the United States, China, and international markets. The company's lead product candidate, LCAR-B38M, is a chimeric antigen receptor (CAR-T) therapy designed to treat multiple myeloma, including cases refractory to standard therapies. Legend Biotech's pipeline includes earlier-stage autologous CAR-T candidates in clinical trials for gastric cancer and T-cell lymphoma, as well as additional CAR-T programs targeting CD20, CD22, and CD19 for non-Hodgkin lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. The company is also developing candidates for solid tumors and infectious diseases. Founded in 2014 and based in Somerset, New Jersey, Legend Biotech operates as a subsidiary of Genscript Biotech Corporation and maintains a collaboration and licensing agreement with Janssen Biotech for the development and commercialization of ciltacabtagene autoleucel.
